Tuberculosis Omics Research Consortium, Family Medicine and Population Health, Faculty of Medicine and Health Sciences, University of Antwerpgrid.5284.b, Antwerp, Belgium.
Adrem Data Lab, Department of Computer Science, Faculty of Sciences, University of Antwerpgrid.5284.b, Antwerp, Belgium.
Antimicrob Agents Chemother. 2022 Jul 19;66(7):e0032222. doi: 10.1128/aac.00322-22. Epub 2022 Jun 27.
Studies have shown that variants in bedaquiline-resistance genes can occur in isolates from bedaquiline-naive patients. We assessed the prevalence of variants in all bedaquiline-candidate-resistance genes in bedaquiline-naive patients, investigated the association between these variants and lineage, and the effect on phenotype. We used whole-genome sequencing to identify variants in bedaquiline-resistance genes in isolates from 509 bedaquiline treatment naive South African tuberculosis patients. A phylogenetic tree was constructed to investigate the association with the isolate lineage background. Bedaquiline MIC was determined using the UKMYC6 microtiter assay. Variants were identified in 502 of 509 isolates (98.6%), with the highest (85%) prevalence of variants in the () gene. We identified 36 unique variants, including 19 variants not reported previously. Only four isolates had a bedaquiline MIC equal to or above the epidemiological cut-off value of 0.25 μg/mL. Phylogenetic analysis showed that 14 of the 15 variants observed more than once occurred monophyletically in one Mycobacterium tuberculosis (sub)lineage. The bedaquiline MIC differed between isolates belonging to lineage 2 and 4 (Fisher's exact test, = 0.0004). The prevalence of variants in bedaquiline-resistance genes in isolates from bedaquiline-naive patients is high, but very few (<2%) isolates were phenotypically resistant. We found an association between variants in bedaquiline resistance genes and Mycobacterium tuberculosis (sub)lineage, resulting in a lineage-dependent difference in bedaquiline phenotype. Future studies should investigate the impact of the presence of variants on bedaquiline-resistance acquisition and treatment outcome.
研究表明,在从未使用过贝达喹啉的患者的分离株中可能出现贝达喹啉耐药基因的变异。我们评估了从未使用过贝达喹啉的患者中所有贝达喹啉候选耐药基因变异的流行率,研究了这些变异与谱系之间的关系,以及对表型的影响。我们使用全基因组测序来鉴定 509 例从未使用过贝达喹啉的南非结核病患者分离株中的贝达喹啉耐药基因变异。构建了一个系统发育树来研究与分离株谱系背景的关联。使用英国 MYC6 微量滴定板测定贝达喹啉 MIC。在 509 株分离株中,有 502 株(98.6%)鉴定出了变异,其中()基因的变异率最高(85%)。我们鉴定出 36 个独特的变异,包括 19 个以前未报道过的变异。只有 4 株分离株的贝达喹啉 MIC 等于或高于 0.25μg/ml 的流行病学临界点。系统发育分析表明,观察到的 15 个变异中有 14 个在一个结核分枝杆菌(亚)谱系中呈单系发生。属于谱系 2 和 4 的分离株之间的贝达喹啉 MIC 存在差异(Fisher 精确检验,=0.0004)。从未使用过贝达喹啉的患者的分离株中贝达喹啉耐药基因变异的流行率很高,但表型耐药的分离株很少(<2%)。我们发现贝达喹啉耐药基因变异与结核分枝杆菌(亚)谱系之间存在关联,导致贝达喹啉表型存在谱系依赖性差异。未来的研究应调查变异的存在对贝达喹啉耐药获得和治疗结果的影响。